Genelux (GNLX) IPO deck
Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
This post is for subscribers only
SubscribeAlready have an account? Log in
%20IPO%20deck){kind=link}